ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2017
Comparative Analyses of Immunosuppressive Characteristics of Bone-Marrow, Wharton's Jelly, and Adipose Tissue-Derived Human Mesenchymal Stem Cells.
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases.Immunity, inflammation and disease · 2025Review
- Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.Clinical reviews in allergy & immunology · 2025Review
- Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-generation Myocardial Repair and Regeneration: Mechanisms and Pre-clinical Evidence.Current cardiology reviews · 2025Review
- Administration of adipose tissue-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells in anosmic mice.Turkish journal of medical sciences · 2025Article
- Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review.Health science reports · 2024Article
- Factors Defining Human Adipose Stem/Stromal Cell Immunomodulation in Vitro.Stem cell reviews and reports · 2024Review
- Influence of type 2 diabetes and obesity on adipose mesenchymal stem/stromal cell immunoregulation.Cell and tissue research · 2023Review
- Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023Review
- Immunomodulatory Functions of Adipose Mesenchymal Stromal/Stem Cell Derived From Donors With Type 2 Diabetes and Obesity on CD4 T Cells.Stem cells (Dayton, Ohio) · 2023Article
- Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes.Frontiers in immunology · 2023Article
- Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.Journal of cellular and molecular medicine · 2022Review
- Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications.Stem cells international · 2022Review
- Comparison of similar cells: Mesenchymal stromal cells and fibroblasts.Acta histochemica · 2020Review
- Mesenchymal stem cells as a multimodal treatment for nervous system diseases.Stem cells translational medicine · 2020Review
- Clinical-based Cell Therapies for Heart Disease-Current and Future State.Rambam Maimonides medical journal · 2020Review
- Human Wharton's Jelly-Cellular Specificity, Stemness Potency, Animal Models, and Current Application in Human Clinical Trials.Journal of clinical medicine · 2020Review
- Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro.Stem cell research & therapy · 2020Article
- Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia.Therapeutic advances in hematology · 2020Article
- Feasibility, potency, and safety of growing human mesenchymal stem cells in space for clinical application.NPJ microgravity · 2020Article
- Can Wharton jelly derived or adipose tissue derived mesenchymal stem cell can be a treatment option for duchenne muscular dystrophy? Answers as transcriptomic aspect.American journal of stem cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMesenchymal stem cells (MSCs), which possess immunosuppressive characteristics on induced T-cells, were shown to be applicable in prevention and treatment of graft-versus-host disease. However, knowledge of effective cell sources is still limited. In this study, MSCs from different human tissues, i.e. bone marrow (BM), Wharton's jelly (WJ), and adipose tissue, were isolated, and the immune suppression of stimulated T cells was analyzed comparatively. MATERIALS AND
methodsMSCs were co-cultured with phytohemagglutinin-induced T-cells with co-culture techniques with and without cell-to-cell contact. After co-culture for 24 and 96 h, the proliferation rate of T cells was estimated by carboxyfluorescein succinimidyl ester and apoptosis by annexin V/PI methods. Both T cells and MSCs were analyzed with respect to gene expressions by real-time polymerase chain reaction and their specific protein levels by ELISA.
resultsThe results showed that all three MSC lines significantly suppressed T-cell proliferation; BM-MSCs were most effective. Similarly, T-cell apoptosis was induced most strongly by BM-MSCs in indirect culture. In T cells, the genes in NFkB and tumor necrosis factor pathways were silenced and the caspase pathway was induced after co-culture. These results were confirmed with the measurement of protein levels, like transforming growth factor β1, IL-6, interferon-γ, interleukin (IL)-2, and tumor necrosis factor-α. Additionally, IL-17A was detected in high levels in WJ-MSC co-cultures. We showed that IL-17A-producing Tregs are the key mediators in the treatment of graft-versus-host disease.
conclusionBM-MSCs, which have been used in clinical applications for a while, showed the greatest immunosuppressive effect compared to other MSCs. However, a promising cell source could also be WJ, which is also effective in suppression with fewer ethical concerns. We described the molecular mechanism of WJ-MSCs in allogenic transplants for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.